Chava Kimchi-Sarfaty

List of Publications by Year
in descending order

88	7,457	172207 29	62479 80
papers	citations	h-index	g-index

123	123	123	10563
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity. Science, 2007, 315, 525-528.	6.0	2,230
2	P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.	2.6	956
3	Understanding the contribution of synonymous mutations to human disease. Nature Reviews Genetics, 2011, 12, 683-691.	7.7	815
4	Recent advances in (therapeutic protein) drug development. F1000Research, 2017, 6, 113.	0.8	348
5	Exposing synonymous mutations. Trends in Genetics, 2014, 30, 308-321.	2.9	272
6	Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima. Journal of Molecular Biology, 2008, 383, 281-291.	2.0	230
7	Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer. Cancer Research, 2007, 67, 9609-9612.	0.4	219
8	Silent (Synonymous) SNPs: Should We Care About Them?. Methods in Molecular Biology, 2009, 578, 23-39.	0.4	214
9	A new and updated resource for codon usage tables. BMC Bioinformatics, 2017, 18, 391.	1.2	182
10	Functional Characterization of Coding Polymorphisms in the HumanMDR1 Gene Using a Vaccinia Virus Expression System. Molecular Pharmacology, 2002, 62, 1-6.	1.0	154
11	Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13481-13486.	3.3	147
12	MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer. Cancer Research, 2014, 74, 598-608.	0.4	103
13	Codon and Codon-Pair Usage Tables (CoCoPUTs): Facilitating Genetic Variation Analyses and Recombinant Gene Design. Journal of Molecular Biology, 2019, 431, 2434-2441.	2.0	100
14	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics, 2007, 8, 29-39.	0.6	91
15	Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies. Nucleic Acids Research, 2013, 41, 44-53.	6.5	86
16	Building better drugs: developing and regulating engineered therapeutic proteins. Trends in Pharmacological Sciences, 2013, 34, 534-548.	4.0	77
17	Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus. Thrombosis and Haemostasis, 2020, 120, 1668-1679.	1.8	75
18	Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B. Journal of Medical Genetics, 2017, 54, 338-345.	1.5	66

#	Article	IF	Citations
19	Characterization of Coding Synonymous and Non-Synonymous Variants in ADAMTS13 Using Ex Vivo and In Silico Approaches. PLoS ONE, 2012, 7, e38864.	1.1	61
20	Endogenous factor VIII synthesis from the intron 22â€“inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nature Medicine, 2013, 19, 1318-1324.	15.2	59
21	The sounds of silence: synonymous mutations affect function. Pharmacogenomics, 2007, 8, 527-532.	0.6	47
22	Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design. Scientific Reports, 2020, 10, 15643.	1.6	46
23	High Cloning Capacity of In Vitro Packaged SV40 Vectors with No SV40 Virus Sequences. Human Gene Therapy, 2003, 14, 167-177.	1.4	43
24	Efficient Transduction of Human Hematopoietic Cells with the Human Multidrug Resistance Gene 1 via SV40 Pseudovirions. Human Gene Therapy, 1998, 9, 649-657.	1.4	39
25	In Vitro-Packaged SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer. Human Gene Therapy, 2002, 13, 299-310.	1.4	38
26	Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies. Scientific Reports, 2019, 9, 15449.	1.6	38
27	Efficient Delivery of RNA Interference Effectors via in vitro-Packaged SV40 Pseudovirions. Human Gene Therapy, 2005, 16, 1110-1115.	1.4	35
28	SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer and their Potential Application in Cancer Therapy. Current Pharmaceutical Biotechnology, 2004, 5, 451-458.	0.9	33
29	The importance of <scp>mRNA</scp> structure in determining the pathogenicity of synonymous and nonâ€synonymous mutations in haemophilia. Haemophilia, 2017, 23, e8-e17.	1.0	31
30	The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases Such as Cancer. Methods in Molecular Biology, 2009, 542, 5-54.	0.4	31
31	A Gene-Specific Method for Predicting Hemophilia-Causing Point Mutations. Journal of Molecular Biology, 2013, 425, 4023-4033.	2.0	30
32	A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood, 2017, 129, 896-905.	0.6	30
33	TissueCoCoPUTs: Novel Human Tissue-Specific Codon and Codon-Pair Usage TablesÂBased on Differential Tissue Gene Expression. Journal of Molecular Biology, 2020, 432, 3369-3378.	2.0	28
34	A Single Synonymous Variant (c.354G>A [p.P118P]) in ADAMTS13 Confers Enhanced Specific Activity. International Journal of Molecular Sciences, 2019, 20, 5734.	1.8	23
35	Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene. PLoS ONE, 2015, 10, e0132433.	1.1	22
36	SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. Cancer Gene Therapy, 2006, 13, 648-657.	2.2	21

#	Article	IF	Citations
37	Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. Blood Advances, 2017, 1, 1037-1046.	2.5	20
38	Differences in rhodamine-123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity. Annals of Hematology, 1998, 76, 189-194.	0.8	19
39	Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro. BioTechniques, 2004, 37, 270-275.	0.8	18
40	Inhibition of Multidrug Resistance by SV40 Pseudovirion Delivery of an Antigene Peptide Nucleic Acid (PNA) in Cultured Cells. PLoS ONE, 2011, 6, e17981.	1.1	18
41	Genetic determinants of immunogenicity to factorIXduring the treatment of haemophilia B. Haemophilia, 2015, 21, 210-218.	1.0	18
42	von Willebrand factor/ADAMTSâ€13 interactions at birth: implications for thrombosis in the neonatal period. Journal of Thrombosis and Haemostasis, 2019, 17, 429-440.	1.9	18
43	Gene variants of coagulation related proteins that interact with SARS-CoV-2. PLoS Computational Biology, 2021, 17, e1008805.	1.5	18
44	Pseudovirions as Vehicles for the Delivery of siRNA. Pharmaceutical Research, 2010, 27, 400-420.	1.7	17
45	Paracentric inversion X(q21.2q24) associated with mental retardation in males and normal ovarian function in females. American Journal of Medical Genetics Part A, 1995, 55, 359-362.	2.4	16
46	Transport Activity and Surface Expression of the Na+-Ca2+ Exchanger NCX1 Are Inhibited by the Immunosuppressive Agent Cyclosporin A and by the Nonimmunosuppressive Agent PSC833. Journal of Biological Chemistry, 2002, 277, 2505-2510.	1.6	14
47	A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues. Thrombosis and Haemostasis, 2010, 104, 531-533.	1.8	14
48	Multiple in silico tools predict phenotypic manifestations in congenital thrombotic thrombocytopenic purpura. British Journal of Haematology, 2013, 160, 825-837.	1.2	14
49	Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease. Journal of Thrombosis and Haemostasis, 2017, 15, 2306-2316.	1.9	14
50	Splicing dysregulation contributes to the pathogenicity of several F9 exonic point variants. Molecular Genetics & Genomic Medicine, 2019, 7, e840.	0.6	13
51	Cyclosporin A Impairs the Secretion and Activity of ADAMTS13 (A Disintegrin and Metalloprotease with) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	12
52	Analysis of F9 point mutations and their correlation to severity of haemophilia B disease. Haemophilia, 2012, 18, 933-940.	1.0	12
53	Characterization of Conformation-Sensitive Antibodies to ADAMTS13, the von Willebrand Cleavage Protease. PLoS ONE, 2009, 4, e6506.	1.1	12
54	Cyclosporin A-Dependent Downregulation of the Na+/Ca2+ Exchanger Expression. Annals of the New York Academy of Sciences, 2007, 1099, 204-214.	1.8	9

#	Article	IF	Citations
55	Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes. Journal of the National Cancer Institute, 2022, 114, 1072-1094.	3.0	9
56	Modulation of Na⁺-Ca²⁺Exchanger Expression by Immunosuppressive Drugs Is Isoform-Specific. Molecular Pharmacology, 2008, 73, 1254-1263.	1.0	8
57	SNPs in ADAMTS13. Pharmacogenomics, 2011, 12, 1147-1160.	0.6	8
58	Plasma derivatives: New products and new approaches. Biologicals, 2012, 40, 191-195.	0.5	8
59	The Kazusa codon usage database, CoCoPUTs, and the value of up-to-date codon usage statistics. Infection, Genetics and Evolution, 2019, 73, 266-268.	1.0	8
60	Detection of a secreted metalloprotease within the nuclei of liver cells. Molecular BioSystems, 2011, 7, 2012.	2.9	7
61	Translational and transcriptional responses in human primary hepatocytes under hypoxia. American Journal of Physiology - Renal Physiology, 2019, 316, G720-G734.	1.6	7
62	Single-nucleotide variations defining previously unreportedADAMTS13haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family. British Journal of Haematology, 2014, 165, 154-158.	1.2	5
63	In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2. Open Forum Infectious Diseases, 2021, 8, ofab189.	0.4	5
64	Detecting SNP-Induced Structural Changes in RNA: Application to Disease Studies. Lecture Notes in Computer Science, 2012, , 241-243.	1.0	5
65	The Synonymous V107V Mutation In Factor IX Is Not So Silent and May Cause Hemophilia B In Patients. Blood, 2010, 116, 2197-2197.	0.6	5
66	Compounding variants rescue the effect of a deleterious ADAMTS13 mutation in a child with severe congenital heart disease. Thrombosis Research, 2017, 158, 98-101.	0.8	4
67	Distinct signatures of codon and codon pair usage in 32 primary tumor types in the novel database CancerCoCoPUTs for cancer-specific codon usage. Genome Medicine, 2021, 13, 122.	3.6	4
68	Structural, functional, and immunogenicity implications of F9 gene recoding. Blood Advances, 2022, 6, 3932-3944.	2.5	4
69	Detection of intracellular ADAMTS13, a secreted zincâ€metalloprotease, via flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2009, 75A, 675-681.	1.1	3
70	Genetic Polymorphisms of P-glycoprotein: Echoes of Silence. , 2016, , 105-134.		3
71	Polyethylene Oxide Molecular Size Determines the Severity of Atypical Thrombotic Microangiopathy in a Guinea Pig Model of Acute Intravenous Exposure. Toxicological Sciences, 2020, 177, 235-247.	1.4	3
72	New approaches to predict the effect of co-occurring variants on protein characteristics. American Journal of Human Genetics, 2021, 108, 1502-1511.	2.6	3

#	Article	IF	Citations
73	Ribosome profiling of HEK293T cells overexpressing codon optimized coagulation factor IX. F1000Research, 2020, 9, 174.	0.8	3
74	NCX1 Surface Expression. Annals of the New York Academy of Sciences, 2002, 976, 176-186.	1.8	2
75	Personalized approaches to the treatment of hemophilia A and B. Personalized Medicine, 2015, 12, 403-415.	0.8	2
76	In silico features of ADAMTS13 contributing to plasmatic ADAMTS13 levels in neonates with congenital heart disease. Thrombosis Research, 2020, 193, 66-76.	0.8	2
77	Ribosome profiling of HEK293T cells overexpressing codon optimized coagulation factor IX. F1000Research, 2020, 9, 174.	0.8	2
78	NCX1 surface expression: a tool to identify structural elements of functional importance. Annals of the New York Academy of Sciences, 2002, 976, 176-86.	1.8	2
79	SV40 In Vitro Packaging: A Pseudovirion Gene Delivery System. Cold Spring Harbor Protocols, 2012, 2012, pdb.prot071043-pdb.prot071043.	0.2	1
80	Higher-Order Structure and Protein Aggregate Characterization of Protein Therapeutics: Perspectives from Good Manufacturing Practices and Regulatory Guidance. , 2013, , 261-281.		1
81	Factor <scp>IX</scp> oligomerization underlies reduced activity upon disruption of physiological conditions. Haemophilia, 2014, 20, e157-63.	1.0	1
82	Selectable Markers for Gene Therapy. , 2015, , 701-740.		0
83	Gene Expression and Detection. , 2003, , 413-480.		0
84	Efficient Delivery of RNA Interference Effectors via In Vitro-Packaged SV40 Pseudovirions. Human Gene Therapy, 2005, .	1.4	0
85	Selectable Markers for Gene Therapy. , 2008, , .		0
86	Secretion and Activity of ADAMTS13 Are Impaired by Cyclosporin A. Blood, 2012, 120, 3349-3349.	0.6	0
87	ADAMTS13: The von Willebrand Factor Cleaving Protease and Its Role in Thrombotic Thrombocytopenic Purpura. , 2013, , 257-276.		0
88	An Optimized Purification Design for Extracting Active ADAMTS13 from Conditioned Media. Processes, 2022, 10, 322.	1.3	0